Accelerate Diagnostics Valuation
| AXDX Stock | USD 0.74 0.08 9.76% |
Accelerate Diagnostics is overvalued. Accelerate Diagnostics shows a prevailing Real Value of $0.71 per share. The current price of the firm is $0.74. Our model approximates the value of Accelerate Diagnostics from analyzing the firm fundamentals such as current valuation of 45.72 M, and Return On Asset of -0.7 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend. Key fundamental drivers impacting Accelerate Diagnostics' valuation include:
Enterprise Value 45.7 M | Enterprise Value Ebitda (0.91) | Price Sales 1.5953 | Enterprise Value Revenue 3.7515 |
Overvalued
Today
Please note that Accelerate Diagnostics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Accelerate Diagnostics is based on 3 months time horizon. Increasing Accelerate Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Accelerate Diagnostics is useful when determining the fair value of the Accelerate stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Accelerate Diagnostics. Since Accelerate Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Accelerate Stock. However, Accelerate Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.74 | Real 0.71 | Target 9.0 | Hype 0.74 | Naive 0.78 |
The real value of Accelerate Stock, also known as its intrinsic value, is the underlying worth of Accelerate Diagnostics Company, which is reflected in its stock price. It is based on Accelerate Diagnostics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Accelerate Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Accelerate Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Accelerate Diagnostics helps investors to forecast how Accelerate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Accelerate Diagnostics more accurately as focusing exclusively on Accelerate Diagnostics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Accelerate Diagnostics' intrinsic value based on its ongoing forecasts of Accelerate Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Accelerate Diagnostics' closest peers. When choosing an evaluation method for Accelerate Diagnostics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Accelerate Diagnostics Investments |
|
Accelerate Valuation Trend
Knowing Accelerate Diagnostics' actual value is paramount for traders to make sound investment determinations. Accelerate Diagnostics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Accelerate Diagnostics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Accelerate Diagnostics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Accelerate Market Cap
Accelerate Diagnostics is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is presently estimated at about 434.89 Billion. Accelerate Diagnostics adds roughly 19.71 Million in market capitalization claiming only tiny portion of equities under Health Care industry.Accelerate Diagnostics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Accelerate Diagnostics's current stock value. Our valuation model uses many indicators to compare Accelerate Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Accelerate Diagnostics competition to find correlations between indicators driving Accelerate Diagnostics's intrinsic value. More Info.Accelerate Diagnostics is rated below average in price to earning category among related companies. It is rated below average in price to sales category among related companies . At this time, Accelerate Diagnostics' Price To Sales Ratio is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Accelerate Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Accelerate Diagnostics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Accelerate Diagnostics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Accelerate Diagnostics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Accelerate Diagnostics and how it compares across the competition.
About Accelerate Diagnostics Valuation
The stock valuation mechanism determines the current worth of Accelerate Diagnostics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Accelerate Diagnostics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Accelerate Diagnostics based exclusively on its fundamental and basic technical indicators. By analyzing Accelerate Diagnostics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Accelerate Diagnostics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Accelerate Diagnostics. We calculate exposure to Accelerate Diagnostics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Accelerate Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.5 M | 1.6 M | |
| Pretax Profit Margin | (5.04) | (5.29) | |
| Operating Profit Margin | (4.48) | (4.70) | |
| Net Loss | (5.11) | (5.37) | |
| Gross Profit Margin | 0.21 | 0.20 |
8 Steps to conduct Accelerate Diagnostics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Accelerate Diagnostics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Accelerate Diagnostics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Accelerate Diagnostics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Accelerate Diagnostics' revenue streams: Identify Accelerate Diagnostics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Accelerate Diagnostics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Accelerate Diagnostics' growth potential: Evaluate Accelerate Diagnostics' management, business model, and growth potential.
- Determine Accelerate Diagnostics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Accelerate Diagnostics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Accelerate Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Accelerate Diagnostics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.5 M |
Accelerate Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Accelerate Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Accelerate we look at many different elements of the entity such as Accelerate's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Accelerate Diagnostics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Accelerate Diagnostics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Accelerate Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Accelerate Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Accelerate Diagnostics' worth.When determining whether Accelerate Diagnostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Accelerate Diagnostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Accelerate Diagnostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Accelerate Diagnostics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.